Veranova announced the appointment of William Sanders as global vice president of chemical development operations.

With more than 25 years in the chemical and pharmaceutical industries, Sanders brings a wealth of experience to Veranova across multiple pharmaceutical modalities, including complex APIs, highly potent APIs (HPAPIs) and antibody drug conjugate (ADC) payload-linkers.

Sanders most recently served as senior director of R&D at Actylis, where he oversaw a global R&D organization comprising approximately 60 scientists. At Actylis, his collaboration with the business development team contributed significantly to the provision of essential technical support to clients and prospects. Prior to Actylis, he dedicated 16 years of expertise to MilliporeSigma/SAFC, where he gained significant experience with highly potent APIs, including vitamin D analogs, sex hormones and various small-molecule oncology drugs, as well as all classes of payloads used in ADCs currently in clinical development. He has worked on 10 of the 13 FDA-approved ADCs to date.

Sanders also has extensive experience in flash chromatography, including developing and implementing organic solvent and water-based chromatographic methods for cGMP production. He also has extensive experience in Quality and Regulatory requirements at all stages of the development cycle from pre-clinical through commercial.

“We are delighted to welcome Dr. William Sanders as our global vice President of chemical development operations,” said Rohtash Kumar, senior vice president of development operations and chief technology officer at Veranova. “His wealth of experience and track record of excellence make him a valuable asset to our team as we continue to advance our global R&D strategy and drive pharmaceutical success for our partners.”